STOCK TITAN
  1. Home
  2. News
  3. BPTH
  4. Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Bio-Path Holdings (OTCQB: BPTH), a clinical-stage biotech company, received updated coverage from Stonegate Capital Partners for Q1 2025. The company specializes in RNA interference therapeutics using its DNAbilize platform technology, which delivers antisense oligonucleotides with neutral charge and reduced toxicity. Their lead drug candidate prexigebersen (BP1001) targets Grb2 protein and is in Phase 2 trials for acute myeloid leukemia (AML). The company's pipeline includes BP1001-A in Phase 1/1b for solid tumors, BP1002 targeting Bcl-2 for blood cancers and solid tumors, and BP1003, a STAT3 inhibitor for pancreatic cancer awaiting IND application. Phase 2 data for prexigebersen shows promising potential for FDA approval in AML treatment.
Bio-Path Holdings (OTCQB: BPTH), una società biotecnologica in fase clinica, ha ricevuto un aggiornamento di copertura da Stonegate Capital Partners per il primo trimestre 2025. L'azienda è specializzata in terapie basate sull'interferenza dell'RNA utilizzando la sua tecnologia piattaforma DNAbilize, che consente la somministrazione di oligonucleotidi antisenso con carica neutra e ridotta tossicità. Il loro principale candidato farmaco, prexigebersen (BP1001), che mira alla proteina Grb2, è attualmente in studi di Fase 2 per la leucemia mieloide acuta (AML). Il portafoglio prodotti include BP1001-A in Fase 1/1b per tumori solidi, BP1002 che prende di mira Bcl-2 per tumori ematici e solidi, e BP1003, un inibitore di STAT3 per il cancro al pancreas in attesa di domanda IND. I dati di Fase 2 su prexigebersen mostrano un potenziale promettente per l'approvazione FDA nel trattamento dell'AML.
Bio-Path Holdings (OTCQB: BPTH), una compañía biotecnológica en etapa clínica, recibió una actualización de cobertura por parte de Stonegate Capital Partners para el primer trimestre de 2025. La empresa se especializa en terapias de interferencia de ARN utilizando su tecnología de plataforma DNAbilize, que entrega oligonucleótidos antisentido con carga neutra y toxicidad reducida. Su principal candidato a medicamento, prexigebersen (BP1001), que apunta a la proteína Grb2, está en ensayos de Fase 2 para leucemia mieloide aguda (LMA). La cartera incluye BP1001-A en Fase 1/1b para tumores sólidos, BP1002 dirigido a Bcl-2 para cánceres de sangre y tumores sólidos, y BP1003, un inhibidor de STAT3 para cáncer de páncreas que espera la solicitud IND. Los datos de Fase 2 de prexigebersen muestran un potencial prometedor para la aprobación de la FDA en el tratamiento de LMA.
Bio-Path Holdings(OTCQB: BPTH)는 임상 단계의 바이오텍 회사로, Stonegate Capital Partners로부터 2025년 1분기 업데이트 리포트를 받았습니다. 이 회사는 DNAbilize 플랫폼 기술을 활용한 RNA 간섭 치료제에 특화되어 있으며, 중성 전하와 낮은 독성을 가진 안티센스 올리고뉴클레오티드를 전달합니다. 주요 후보 약물인 프렉시게버센(BP1001)은 Grb2 단백질을 표적으로 하며, 급성 골수성 백혈병(AML)을 위한 2상 임상 시험 중입니다. 파이프라인에는 고형암 대상 1/1b상 BP1001-A, 혈액암 및 고형암 대상 Bcl-2 표적 BP1002, 췌장암용 STAT3 억제제인 BP1003(IND 신청 대기 중)이 포함되어 있습니다. 프렉시게버센의 2상 데이터는 AML 치료를 위한 FDA 승인 가능성을 보여주고 있습니다.
Bio-Path Holdings (OTCQB : BPTH), une société biotechnologique en phase clinique, a reçu une mise à jour de couverture de Stonegate Capital Partners pour le premier trimestre 2025. L'entreprise se spécialise dans les thérapies par interférence ARN utilisant sa technologie de plateforme DNAbilize, qui délivre des oligonucléotides antisens à charge neutre et à toxicité réduite. Leur principal candidat médicament, le préxigébersen (BP1001), cible la protéine Grb2 et est en essais de phase 2 pour la leucémie myéloïde aiguë (LMA). Le portefeuille comprend BP1001-A en phase 1/1b pour les tumeurs solides, BP1002 ciblant Bcl-2 pour les cancers du sang et les tumeurs solides, ainsi que BP1003, un inhibiteur de STAT3 pour le cancer du pancréas en attente de dépôt de demande IND. Les données de phase 2 pour le préxigébersen montrent un potentiel prometteur pour une approbation FDA dans le traitement de la LMA.
Bio-Path Holdings (OTCQB: BPTH), ein biotechnologisches Unternehmen in der klinischen Phase, erhielt ein aktualisiertes Coverage von Stonegate Capital Partners für das erste Quartal 2025. Das Unternehmen spezialisiert sich auf RNA-Interferenz-Therapeutika unter Verwendung seiner DNAbilize-Plattformtechnologie, die antisense Oligonukleotide mit neutraler Ladung und reduzierter Toxizität liefert. Ihr führender Arzneimittelkandidat Prexigebersen (BP1001) zielt auf das Grb2-Protein ab und befindet sich in Phase-2-Studien zur Behandlung der akuten myeloischen Leukämie (AML). Die Pipeline umfasst BP1001-A in Phase 1/1b für solide Tumore, BP1002, das Bcl-2 für Blutkrebs und solide Tumore anvisiert, sowie BP1003, einen STAT3-Inhibitor für Bauchspeicheldrüsenkrebs, der auf die IND-Anmeldung wartet. Phase-2-Daten zu Prexigebersen zeigen vielversprechendes Potenzial für eine FDA-Zulassung bei der AML-Behandlung.
Positive
  • Phase 2 prexigebersen data indicates potential for FDA approval in AML treatment
  • BP1001-A showing early efficacy signs in advanced solid tumors
  • Diversified pipeline with multiple drug candidates in development
  • Robust patent portfolio protecting proprietary technology
Negative
  • Company trades on OTCQB market rather than major exchange
  • Early clinical stage company with no approved products yet
  • Multiple ongoing trials require significant capital expenditure

Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Phase 2 prexigebersen data shows potential for FDA approval in AML treatment.
  • BP1001-A trial shows early signs of efficacy in advanced solid tumors.
  • Advancing pipeline backed by strategic R&D and a robust patent portfolio.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/254522_figure1_550.jpg

Click image above to view full announcement.

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.

Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254522

FAQ

What is Bio-Path Holdings' (BPTH) main drug candidate and its current development stage?

Bio-Path's lead drug candidate is prexigebersen (BP1001), which targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML).

What is Bio-Path Holdings' (BPTH) proprietary technology platform?

Bio-Path utilizes the DNAbilize platform technology, which delivers neutral-charge, liposomal antisense oligonucleotides with enhanced drug stability and cellular uptake while minimizing toxicity.

What are the key drug candidates in Bio-Path Holdings' (BPTH) pipeline?

The pipeline includes prexigebersen (BP1001) for AML, BP1001-A for solid tumors, BP1002 targeting Bcl-2 for blood cancers and solid tumors, and BP1003 for pancreatic cancer.

What were the main updates in Stonegate Capital Partners' Q1 2025 coverage of BPTH?

The coverage highlighted Phase 2 prexigebersen data showing potential for FDA approval in AML treatment, BP1001-A's early efficacy in advanced solid tumors, and the company's advancing pipeline supported by strategic R&D and patent portfolio.

What additional indications is Bio-Path Holdings (BPTH) exploring with BP1001-A?

BP1001-A has shown promise in preclinical studies for obesity and type 2 diabetes, in addition to its current Phase 1/1b trials for solid tumors.
Stock BPTH logo
Bio-Path Hldgs Inc

OTC:BPTH

BPTH Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BPTH Latest News

Jun 3, 2025
Bio-Path Holdings Provides Clinical and Operational Update
May 22, 2025
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
May 1, 2025
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Mar 28, 2025
Bio-Path Holdings Reports Full Year 2024 Financial Results
Mar 18, 2025
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BPTH Stock Data

4.66M
8.31M
0.02%
3.84%
1.38%
Biotechnology
Pharmaceutical Preparations
Link
United States
BELLAIRE

Related Articles

Continue reading with these related stories

View All Latest News